Rein Therapeutics (RNTX) Accounts Payables (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Accounts Payables of $6.3 million for Q1 2026, up 445.08% year-over-year from $1.1 million in Q1 2025, and up 57.52% quarter-over-quarter from $4.0 million in Q4 2025.
Rein Therapeutics (RNTX) Accounts Payables (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Accounts Payables for 11 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 445.08% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $6.3 million (up 445.08% YoY), while the FY2025 annual figure was $4.0 million, up 336.44% from the prior year.
- Accounts Payables grew to $6.3 million in Q1 2026 per RNTX's latest filing, from $4.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $6.3 million in Q1 2026 and bottomed at $136000.0 in Q2 2023.
- Historically, Accounts Payables has averaged $2.0 million across 5 years, with a median of $1.1 million in 2025.
- Annual changes were most pronounced in 2023 — Accounts Payables plunged 92.19% — and 2025, when it soared 670.84%.
- Rein Therapeutics' Accounts Payables stood at $1.7 million in 2022, then slumped by 30.81% to $1.2 million in 2023, then retreated by 23.45% to $911000.0 in 2024, then jumped by 336.44% to $4.0 million in 2025, then soared by 57.52% to $6.3 million in 2026.
- Business Quant data shows RNTX's Accounts Payables at $6.3 million in Q1 2026, $4.0 million in Q4 2025, and $4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.47 Mn |
| Mar 31, 2026 | 6.26 Mn |
| Dec 31, 2025 | 3.98 Mn |
| Sep 30, 2025 | 4.12 Mn |
| Jun 30, 2025 | 6.03 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 911,000.00 |
| Sep 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 782,000.00 |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | 1.19 Mn |
| Sep 30, 2023 | 484,000.00 |
| Jun 30, 2023 | 136,000.00 |
| Mar 31, 2023 | 458,000.00 |
| Dec 31, 2022 | 1.72 Mn |
| Sep 30, 2022 | 945,000.00 |
| Jun 30, 2022 | 1.74 Mn |
| Mar 31, 2022 | 1.02 Mn |
| Dec 31, 2021 | 1.21 Mn |
| Sep 30, 2021 | 1.04 Mn |